Recurrent Primary Peritoneal Carcinoma (DBCOND0031168)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05554328	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	Hydrogen Olaparib Selumetinib Sulfate ion	treatment	2	recruiting
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Alpelisib Binimetinib Fluorouracil Fulvestrant Hydrogen Ipatasertib Leucovorin Neratinib Nilotinib Olaparib Oxaliplatin Paclitaxel Palbociclib Panitumumab Selumetinib Sotorasib Sulfate ion	screening	2	recruiting
NCT06483048	MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer	Bendamustine Cyclophosphamide	treatment	1	recruiting
NCT02446600	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Cediranib Doxorubicin Gemcitabine Olaparib Paclitaxel Tetracycline	treatment	3	active_not_recruiting
NCT03604315	Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF	No drug interventions	treatment	1	recruiting
NCT05691504	Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	Cobimetinib Pelcitoclax	treatment	1	recruiting
NCT03206047	Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Atezolizumab Cancer/testis antigen 1 Carboxymethylcellulose Guadecitabine Hiltonol Lysine Polyinosinic-polycytidylic acid Rasdegafusp alfa	treatment	1 / 2	active_not_recruiting
NCT05231122	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer	Bevacizumab Pembrolizumab	treatment	2	recruiting
NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	Bevacizumab Sapanisertib	treatment	1	active_not_recruiting
NCT04469764	Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer	Abemaciclib Anastrozole Letrozole	treatment	2	recruiting
NCT02312245	Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Doxorubicin Gemcitabine Paclitaxel Tetracycline Topotecan	treatment	2	completed
NCT03586661	Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Copanlisib Niraparib	treatment	1	active_not_recruiting
NCT02657928	Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer	Letrozole Ribociclib	treatment	2	completed
NCT01074411	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bortezomib Bortezomib D-mannitol Carboplatin	treatment	1	completed
NCT01294293	TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Doxorubicin Motolimod Paclitaxel	treatment	1	completed
NCT03552471	Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Mirvetuximab Mirvetuximab soravtansine Rucaparib	treatment	1	active_not_recruiting
NCT01489371	EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Cholesterol Doxorubicin EGEN-001 Tetracycline	treatment	1	completed
NCT04781088	Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Lenvatinib Paclitaxel Pembrolizumab	treatment	2	active_not_recruiting
NCT02839707	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Atezolizumab Bevacizumab Doxorubicin Tetracycline	treatment	2 / 3	active_not_recruiting
NCT01039207	Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Rilotumumab	treatment	2	completed
NCT01468909	Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Paclitaxel Pazopanib	treatment	2	completed
NCT00888615	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Elesclomol Paclitaxel	treatment	2	completed
NCT00096200	Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Carboplatin Paclitaxel Sorafenib	treatment	2	completed
NCT02470559	Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent	Aldesleukin Muromonab Sargramostim	treatment	1	withdrawn
NCT02208375	mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian	Capivasertib Olaparib Vistusertib	treatment	1 / 2	active_not_recruiting
NCT04092270	A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	Benzalkonium Doxorubicin Nedisertib Tetracycline	treatment	1	recruiting
NCT03539406	Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients	Natural Killer Cell	treatment	1	completed
NCT03968406	Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	Talazoparib	treatment	1	recruiting
NCT00892736	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy	Veliparib	treatment	1	completed
NCT01305213	Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer	Bevacizumab Fosbretabulin	treatment	2	completed
NCT01606241	Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Benzalkonium Cyclophosphamide Folic acid	treatment	1	completed
NCT03325634	Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer	No drug interventions	treatment	1	completed
NCT03579316	Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Adavosertib Ceralasertib Olaparib	treatment	2	recruiting
NCT02283658	Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Everolimus Letrozole	treatment	2	completed
NCT01283035	A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer	No drug interventions	treatment	2	completed
NCT02923739	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Emactuzumab Paclitaxel	treatment	2	terminated
NCT02275039	p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer	Gemcitabine Modified vaccinia ankara	treatment	1	completed
NCT02996825	Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer	Gemcitabine Mirvetuximab Mirvetuximab soravtansine	treatment	1	completed
NCT01145430	Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer	Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT02315430	Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Cabozantinib	treatment	2	completed
NCT02569957	Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Acetylcysteine Topotecan	treatment	2	terminated
NCT01010126	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	Bevacizumab Menthol Sirolimus Temsirolimus	treatment	2	completed
NCT01540565	Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Veliparib	treatment	2	completed
NCT00954174	Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer	Carboplatin Cyclophosphamide Ifosfamide Paclitaxel	treatment	3	unknown_status
NCT04498520	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	Abexinostat Fulvestrant Palbociclib	treatment	1	withdrawn
NCT01492920	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy	No drug interventions	supportive_care	3	withdrawn
NCT01720173	Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Dalantercept	treatment	2	completed
NCT03907527	Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT01459380	Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Bevacizumab Carboplatin Doxorubicin Tetracycline Veliparib	treatment	1	completed
NCT02595892	Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Berzosertib Gemcitabine	treatment	2	active_not_recruiting
NCT01001910	Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Carboplatin Pemetrexed	treatment	2	completed
NCT03685695	Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	No drug interventions	supportive_care	2	completed
NCT02627443	Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Berzosertib Carboplatin Gemcitabine	treatment	1	active_not_recruiting
NCT01175343	RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	RG-4733	treatment	2	completed
NCT01372787	Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer	No drug interventions	Not Available	Not Available	unknown_status
NCT00565851	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Docetaxel Gemcitabine Paclitaxel	treatment	3	active_not_recruiting
NCT00602277	Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy	Pelareorep	treatment	1	completed
NCT03924245	Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	Entinostat Olaparib	treatment	1	terminated
NCT03029598	Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Pembrolizumab	treatment	1 / 2	completed
NCT05920798	A Study of FRaDCs for Ovarian Cancer	Folic acid Pembrolizumab	treatment	1 / 2	recruiting
NCT00671788	A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	Dasatinib	treatment	2	completed
NCT04019288	AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Batiraxcept Durvalumab	treatment	1 / 2	active_not_recruiting
NCT01716715	Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Cabozantinib Paclitaxel	treatment	2	completed
NCT01264432	Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	Veliparib	treatment	1	completed
NCT02498600	Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Ipilimumab Nivolumab	treatment	2	active_not_recruiting
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Adavosertib Gemcitabine	treatment	2	active_not_recruiting
NCT03508570	Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis	Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT00897442	Collecting Tumor Samples From Patients With Gynecological Tumors	No drug interventions	Not Available	Not Available	completed
NCT02901899	Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Guadecitabine Pembrolizumab	treatment	2	completed
NCT02833506	Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Baloramotide Sirolimus	treatment	1	withdrawn
NCT04055649	ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer	Benzalkonium Dordaviprone Paclitaxel	treatment	2	recruiting
NCT02364713	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	Bevacizumab Doxorubicin Gemcitabine Measles virus vaccine live attenuated Paclitaxel Sodium iodide Tetracycline Topotecan	treatment	2	active_not_recruiting
NCT02853318	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Cyclophosphamide Pembrolizumab	treatment	2	completed
NCT02111941	Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	Folic acid	treatment	0	active_not_recruiting
NCT01012817	Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer	Topotecan Veliparib	treatment	1 / 2	active_not_recruiting
NCT04753216	Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Irinotecan	treatment	2	completed
NCT01199263	Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Paclitaxel Pelareorep	treatment	2	completed
NCT01970722	Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer	Carboplatin Chloride ion Cisplatin Doxorubicin Gemcitabine Paclitaxel Platinum Tetracycline	treatment	1	active_not_recruiting
NCT02756130	Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Birinapant Carboplatin	treatment	1 / 2	withdrawn
NCT02627430	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer	Onalespib Talazoparib	treatment	1	withdrawn
NCT03412630	Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab	No drug interventions	diagnostic	Not Available	terminated
NCT02953457	Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	Durvalumab Olaparib Tremelimumab	treatment	2	active_not_recruiting
NCT02502266	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	Cediranib Doxorubicin Olaparib Paclitaxel Tetracycline Topotecan	treatment	2 / 3	active_not_recruiting
NCT02059265	Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer	Dasatinib	treatment	2	terminated
NCT06295965	Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers, CHANCES Study	No drug interventions	Not Available	Not Available	recruiting
NCT03017131	Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Aldesleukin Cancer/testis antigen 1 Cyclophosphamide Decitabine	treatment	1	active_not_recruiting
NCT04387227	Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Carboplatin Pembrolizumab	treatment	2	recruiting
NCT04034927	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	Olaparib Tremelimumab	treatment	2	active_not_recruiting
NCT03691376	Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Aldesleukin Cancer/testis antigen 1 Mechlorethamine	treatment	1	active_not_recruiting
NCT02068794	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Measles virus vaccine live attenuated Sodium iodide	treatment	1 / 2	active_not_recruiting
NCT04213794	Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients	Chloride ion Cisplatin Daunorubicin Doxorubicin Platinum Thiosulfuric acid	treatment	0	active_not_recruiting
NCT00886691	Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bevacizumab Everolimus	treatment	2	completed
NCT03026062	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Durvalumab Tremelimumab	treatment	2	recruiting
NCT04919629	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	Bevacizumab Pegcetacoplan Pembrolizumab	treatment	2	recruiting
NCT02948101	PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Cyclophosphamide	treatment	2	withdrawn
NCT03776812	Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Paclitaxel Relacorilant	treatment	2	unknown_status
NCT05672095	Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer	Niraparib Selenium	treatment	1 / 2	not_yet_recruiting
NCT03732950	Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer	Pembrolizumab	treatment	2	active_not_recruiting